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Abstract
Paraneoplastic neurological syndromes (PNS) are often characterized by the
presence of antineuronal antibodies in patient serum or cerebrospinal fluid.
The detection of antineuronal antibodies has proven to be a useful tool in PNS
diagnosis and the search for an underlying tumor. Here, we describe three
patients with autoantibodies to several epitopes of the axon initial segment pro-
tein tripartite motif 46 (TRIM46). We show that anti-TRIM46 antibodies are
easy to detect in routine immunohistochemistry screening and can be con-
firmed by western blotting and cell-based assay. Anti-TRIM46 antibodies can
occur in patients with diverse neurological syndromes and are associated with
small-cell lung carcinoma.
Introduction
Paraneoplastic neurological syndromes (PNS) include a
variety of immune-mediated neurological disorders that
occur in association with cancer. PNS is caused by an
immune reaction directed at an autoantigen that is shared
by neurons and cancer cells. Mostly, the neurological
symptoms precede the diagnosis of cancer. Early recogni-
tion of PNS can facilitate tumor detection and treatment
and thereby increases the chance of stabilizing the neuro-
logical symptoms.1
The immune reaction in PNS is often hallmarked by
the presence of antineuronal antibodies in patient serum
or cerebrospinal fluid (CSF). The detection of antineu-
ronal antibodies has proven to be a useful tool in PNS
diagnosis. Some antineuronal antibodies, such as anti-
DNER (Tr), are very syndrome and tumor specific.2,3
Others, such as anti-Hu, are associated with a variety of
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neurological syndromes but predict an underlying small-
cell lung carcinoma (SCLC) in most cases.4
Autoantibodies to components of the axon initial seg-
ment (AIS) and (para)nodes of Ranvier (NOR) have been
reported in PNS and other neurological disorders.5–8 The
AIS and NOR are molecularly related axonal regions that
are involved in the initiation and propagation of action
potentials.9 Recently, the protein tripartite motif 46
(TRIM46) was found to be the autoantigen in a patient
with paraneoplastic encephalomyelitis (PEM) and anti-
bodies to the AIS but not the NOR of the sciatic
nerve.6,10 TRIM46 localizes specifically to the proximal
axon where it bundles parallel microtubules and is impor-
tant for axon specification and outgrowth during early
brain development.10
Here, we clinically and experimentally characterize
three patients with antibodies to TRIM46. We show that
TRIM46 antibodies are associated with the presence of a
SCLC and can present with a broad clinical variety of
central nervous system (CNS) symptoms.
Materials and Methods
Patients with AIS staining were identified in two European
PNS laboratories (Erasmus University Medical Center
(EMC), Rotterdam, the Netherlands. IDIBAPS, Barcelona,
Spain) that test over 2000 samples yearly for the presence
of onconeuronal antibodies. Routine diagnostic testing was
performed using immunohistochemistry (IHC) of rat brain
slices. The AIS staining patterns of patient 1 and 2 were
previously described.6,11 This study was approved by the
Institutional Review Board of the EMC.
The controls included serum or plasma from 88
anonymous blood bank donors, 20 reumatoid factor-
positive patients, 10 patients with systemic lupus erythe-
matosus, 10 patients with Sj€ogren’s syndrome, 30 patients
with anti-Hu antibodies and SCLC and 50 patients with
SCLC without neurological symptoms (13 with limited
disease, 31 with extensive disease, six with unknown dis-
ease severity) that were previously used in Ref. 12
The following antibodies and reagents were used in this
study: mouse anti-ankyrinG (Life Technologies, Carlsbad,
USA), chicken anti-MAP2 (Abcam, Cambridge, UK),
mouse anti-GFP (Roche, Almere, Netherlands), rabbit
anti-TRIM46 (in-house, generated as described in10), and
Alexa-405, -488, or -568-conjugated secondary antibodies
directed at human, mouse, chicken, or rabbit IgG
(Thermo Fisher, Landsmeer, Netherlands). For western
blotting, horseradish peroxidase-conjugated donkey anti-
human (Calbiochem, Amsterdam, Netherlands) and swine
anti-mouse (DAKO, Heverlee, Belgium) were used. For
immunohistochemistry, biotin-conjugated goat anti-
human IgG antibodies (Vector Laboratories, Youngstown,
USA) and Vectastain Elite ABC complex (Vector Labora-
tories, Youngstown, USA) were used.
The TRIM46 and TRIM36 DNA clones were kindly
provided by Dr. T Cox.13 Expression constructs and chi-
meric constructs were generated in-house by PCR as
described in Ref. 10. Primer sequences are available on
request. Immunohistochemistry of rat brain slices and
SCLC tissue with diaminobenzidine stain was performed
essentially as described in Ref. 14. Fluorescent staining of
brains from P5 C57BL/6 wild-type mice was performed as
described in Ref.10. Primary hippocampal neuron cultures
were obtained according to established procedures.15
DNA transfection and immunofluorescent staining proce-
dures of HeLa cells and neurons and western blotting
were performed as described in Ref.14. Confocal images
were acquired with the Zeiss LSM 700 using the 639 oil
objective.
Results
Routine IHC screening for onconeuronal antibodies
revealed serum samples from three patients with stain-
ing of the AIS throughout the rat brain (Fig. 1A).
Detailed clinical information on these patients can be
found in Table 1. Patient 1 presented with PEM and
SCLC. Patient 2 presented with cerebellar degeneration
and was diagnosed with SCLC 10 months later. Patient
3 presented with rapidly progressive dementia, resem-
bling Creuzfeldt-Jakob disease, without a known under-
lying tumor. No other antineuronal antibodies were
detected. Patient 1 showed no response to oncologic
treatment and died of tumor progression 3 months after
onset of the neurological symptoms. Patient 2 was lost
to follow up and patient 3 died of neurological progres-
sion 7 months after onset of the neurological symptoms.
At autopsy of the brain from patient 3 showed exten-
sive perivascular and parenchymal CD8+ T-cell infiltra-
tion.
To verify the specific labeling of the proximal axon, we
performed double immune labeling using the patients’
sera and the well-known AIS marker ankyrinG (AnkG).
The staining pattern of the patients’ sera largely colocal-
ized with AnkG both in mouse brain (Fig. 1B) and
cultured rat hippocampal neurons (Fig. 1C).
To identify the molecular target of the antibodies, we
tested the reactivity of the patients’ sera against various
AIS proteins. The patients’ antibodies did not react with
bIV-spectrin and AnkG (data not shown). Also, the
patient sera did not label the surface of live hippocampal
neurons, as would be expected for antibodies against neu-
rofascin-186 (NF186). All three sera specifically reacted
with TRIM46 in a cell-based assay (CBA) (Fig. 1D) and
on western blot (Fig. 1E). We tested 208 healthy and
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Figure 1. Identification and validation of TRIM46 as neuronal autoantigen. (A) Immunohistochemistry (IHC) of adult rat brains stained with the patients’
serum. The figures depict a part of the cortex showing prominent staining of the axon initial segment (AIS) (indicated with arrows) by the patients’ sera,
which is absent in the staining with healthy control serum. Scale bars: 50 lm (B) IHC of P5 mouse cortex. The patients’ sera (green) stain the initial part
of the axon and partially colocalize with the AIS marker ankyrinG (red). Scale bars: 20 lm. (C) Immunocytochemistry of cultured rat hippocampal
neurons (DIV25). The patients’ sera (red) stain the initial part of the axon and partially colocalize with the AIS marker ankyrinG (green) but not with the
dendritic marker MAP2 (blue). Scale bars: 20 lm. (D) HeLa cells expressing TRIM46-GFP (green) were fixed, permeabilized and stained with patients’ or
healthy control sera (red). The patients’ sera strongly recognize TRIM46, whereas the control serum does not. Scale bars: 10 lm. (E) Western blots using
lysates of HEK cells overexpressing GFP or TRIM46-GFP. The blots were stained with a GFP antibody, TRIM46 antibody, patients’ or healthy control sera.
The patients’ sera recognize TRIM46-GFP on blot but not GFP. (F) IHC of tumor tissue from patient 1, stained with hematoxylin-eosin (HE), the lung
carcinoma marker thyroid transcription factor 1 (TTF-1), normal rabbit serum, and TRIM46 antibody. The picture shows TRIM46 expression in a subset of
tumor cells. Stainings were performed on sequential slides, pictures were taken in the same area of the sample. Scale bars: 25 lm.
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disease controls of which none reacted with TRIM46 in a
CBA (Fig. 1D, data not shown).
To test whether the immune reaction could have been
triggered by aberrant expression of TRIM46 by the SCLC,
we performed IHC on the SCLC tissue of patient 1. The
patient’s tumor tissue showed specific TRIM46 expression
(Fig. 1F).
Next, we mapped the epitopes of the patients’ antibod-
ies using chimeric constructs of GFP-TRIM46 and -
TRIM36. TRIM36 is a family member that is highly
similar to TRIM4613 but does not localize to axonal
microtubules and is not recognized by the patients’ anti-
bodies. By swapping domains of TRIM46 with the corre-
sponding regions of TRIM36, we were able to identify the
specific domains to which the anti-TRIM46 antibodies
are directed. All three patients had multiple epitopes on
the B-box, coiled-coil, and C-terminal domains of
TRIM46 (Fig. 2).
Conclusion and Discussion
In this article, we describe a novel onconeuronal antibody
directed at the AIS protein TRIM46. We clinically and
experimentally characterize three patients with anti-
TRIM46 antibodies and show that these antibodies are
associated with CNS symptoms and an underlying SCLC.
Anti-TRIM46 antibodies are polyclonal and directed at
multiple, most likely linear epitopes on TRIM46. Anti-
TRIM46 antibodies can robustly be detected with multiple
techniques.
Table 1. Patients’ clinical information.
Patient 1 Patient 2 Patient 3
Gender Male Male Female
Age at disease onset 78 years 64 years 73 years
Neurological syndrome Progressive encephalomyelitis Cerebellar ataxia Rapidly progressive dementia
Main symptoms Gait instability, change of
character, complex partial seizures
Vertigo, nausea, vomiting,
truncal ataxia
Mood disorder, rapidly progressive
dementia, followed by ataxia,
myoclonus, dysarthria, sleep cycle
inversion
Tumor SCLC SCLC No tumor on thoraco-abdominal CT-scan
Brain CT/MRI Normal Normal Bilateral hyperintensity (T2, DWI) in
the head of the caudate and pallidum,
right hippocampus and right anterior
cingular gyrus
EEG Not performed Not performed Progressive diffuse slowing
Blood examination Na 120 mmol/l (SIADH) Normal Normal
CSF examination 1 WBC/lL. Normal protein,
glucose, and cytology.
25 WBC/lL. Normal protein,
glucose, and cytology
14 WBC/lL. Protein: 0.723 g/L. Normal
glucose and cytology. 14-3-3 positive
Paraneoplastic/Neuronal
surface antibodies
Negative (Hu, Yo, Ri, Amp) Negative (Hu, Yo, Ri, Ma1,
Ma2, Tr, Amp, NMDAR,
AMPAR, GABAbR, GABAaR,
LGI1, CASPR2, DPPX, GlycineR,
Zic4, Sox1, CRMP5, GAD65, VGCC)
Negative (Hu, Yo, Ri, Ma1, Ma2, Tr,
Amp, NMDAR, AMPAR, GABAbR,
GABAaR, LGI1, CASPR2, DPPX,
GlycineR, VGKC, Zic4, Sox1, CRMP5,
GAD65)
Treatment Etoposide (1 cycle) Unknown No
Neurological response
to treatment
No Unknown N.A.
Brain autopsy Not performed Not performed Perivascular and parenchymal CD8+
infiltration. Most prominent in limbic
regions. Extensive neuronal loss. No
evidence for CJD
Disease course Change of character, gait
instability and complex partial
seizures developed over weeks.
Diagnosis of SCLC (extensive
disease). After one cycle of
etoposide, the tumor progressed
and the patient died 3 months
after onset of symptoms
Subacute cerebellar and brainstem
symptoms. Diagnosis of SCLC
was made 10 months after onset
of symptoms. Patient was lost
to follow up
Rapidly progressive dementia mimicking
CJD. No tumor was found.
Patient died of neurological progression
7 months after onset of symptoms
SCLC, small-cell lung carcinoma; CJD, Creuzfeldt-Jakob disease; SIADH, syndrome of inappropriate ADH secretion. WBC, white blood cells.
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Figure 2. Epitope mapping of anti-TRIM46 autoantibodies. Schematic representation of TRIM46 (gray) and TRIM36 (white). CC = coiled-coil. COS
= C-terminal subgroup one signature. FN3 = Fibronectin type III. GFP-tagged truncated TRIM46 and chimeric proteins of TRIM46 and TRIM36
(green) expressed in HeLa cells and stained with patient’s serum (red). The patients’ sera recognize the TRIM46 C-terminus and N-terminal B-box,
and CC region.
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Although the number of patients in this case series is
too small to make any general conclusions, the patients’
diverse symptoms fit with the expression of TRIM46
throughout the CNS. A large variety in clinical presenta-
tion is also seen in disorders associated with other
onconeuronal antibodies such as anti-Hu.4 Similar to
anti-Hu, anti-TRIM46 antibodies are associated with an
underlying SCLC. However, although low titers of anti-
Hu antibodies occur in 16–26% of patients with SCLC
without PNS,12,16,17 we did not detect anti-TRIM46 anti-
bodies in sera from patients with SCLC but without neu-
rological symptoms.
TRIM46 antibodies are polyclonal and directed at
immunoreactive epitopes in the B-box, coiled-coil, and
C-terminal domains of TRIM46. A polyclonal immune
reaction, directed at multiple immunogenic sites that are
shared between individual patients, is similar to the well-
studied onconeuronal antigen HuD.18,19 As TRIM46 is a
cytosolic protein, most likely not a humoral but a T-cell-
mediated response against TRIM46 is causing the neuro-
logical dysfunction. The autopsied brain of patient 3
indeed showed infiltration with CD8+ T cells. Also the
poor prognosis of all three patients is in line with irre-
versible neuronal damage. The presence of TRIM46 in the
SCLC of one of the patients suggests that ectopic TRIM46
expression by tumor tissue is the immunological trigger.
However, as an underlying SCLC was not found in one
of the patients, a possible nonparaneoplastic nature of
anti-TRIM46 antibodies cannot be ruled out.
We have only rarely detected staining of the AIS in
routine IHC. In all cases known to us, this was due to
antibodies to TRIM46 and could robustly be confirmed
with multiple laboratory techniques. Autoantibodies to
other components of the AIS have been reported in litera-
ture; for example, antibodies to NF186 have been detected
by ELISA in a small group of patients with peripheral
neuropathies. Their frequency of occurrence varies greatly
between different studies and their clinical value remains
unclear.8 Antibodies to scaffold protein AnkG are present
in patients with Alzheimer’s disease and in up to 25% of
healthy individuals over 65 years of age.7 The discrepancy
between the reported high frequency of AnkG antibodies
and the low frequency of AIS staining on IHC could be
explained by detection methods used (only western blot
for AnkG antibodies). Possibly, the formation of AnkG
antibodies is triggered by neurodegeneration occurring
with age and should be seen separate from the highly
specific antibodies occurring in PNS, such as anti-
TRIM46 antibodies.
In this case series, we show that anti-TRIM46 antibodies
are rare but easy to detect in routine IHC for intracellular
antigens. They can occur in patients with diverse neurologi-
cal syndromes, and can be associated with SCLC.
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